Sustiva
Sustiva Price range: $ 47,00 through $ 2 412,00
Back to products
Symbicort Turbuhaler 60MD
Symbicort Turbuhaler 60MD Price range: $ 42,00 through $ 220,00

Symbicort

Price range: $ 46,00 through $ 132,00

Symbicort is an effective combination medication designed to manage chronic respiratory conditions such as asthma and COPD. It contains two active ingredients, budesonide and formoterol, which work together to reduce airway inflammation and keep breathing passages open. For individuals with asthma, this inhaler helps prevent symptoms like wheezing and shortness of breath through consistent daily use. It is also indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic bronchitis or emphysema. By providing reliable control over respiratory symptoms, Symbicort helps users maintain a more active and comfortable lifestyle.

Active substance: Budesonide, Formoterol
SKU: Symbicort Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Symbicort belongs to a class of combination respiratory medications containing an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol fumarate dihydrate). It is an FDA-approved prescription inhaler designed for long-term maintenance therapy rather than immediate relief of sudden breathing distress. Understanding its proper administration and risk profile helps ensure safe and effective management of chronic airway conditions.

As a daily maintenance treatment, Symbicort combines anti-inflammatory action with bronchodilator support to keep airways open over time. However, like any targeted maintenance regimen, its clinical suitability depends on individual health factors evaluated by a healthcare professional.

Basic Information Overview

Drug Name Symbicort
Active Ingredients Budesonide and formoterol fumarate dihydrate
Therapeutic Class Inhaled corticosteroid (ICS) / Long-acting beta2-adrenergic agonist (LABA) combination
Dosage Form Pressurized metered-dose inhaler (pMDI)
Route of Administration Oral inhalation
Prescription Status Prescription only (Rx)
Primary Indications Asthma maintenance (ages 6 and older), COPD maintenance

Main Uses

Symbicort is indicated for the daily controller treatment of asthma in patients aged 6 years and older, as well as for the maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. On one hand, clinical trials support its efficacy in reducing asthma exacerbations and improving overall lung function parameters over extended periods. On the other hand, it is important to emphasize that Symbicort is not indicated for the relief of acute bronchospasm. Patients must maintain access to a short-acting rescue inhaler, such as albuterol, to address sudden, acute breathing difficulties.

When evaluated in COPD populations, daily use helps decrease the frequency of flare-ups and reduces chronic daytime and nighttime symptoms. However, treatment should be initiated only when a physician confirms that single-agent bronchodilator therapy is insufficient for disease control.

How the Drug Works

The dual active ingredients in Symbicort address chronic airway pathology through distinct yet complementary mechanisms. Budesonide is a corticosteroid with potent local anti-inflammatory activity within the respiratory tract. It works by inhibiting multiple inflammatory cell types (such as mast cells, eosinophils, and lymphocytes) and reducing the secretion of inflammatory mediators. This reduces mucosal edema, airway hyperresponsiveness, and mucus hypersecretion.

Formoterol fumarate dihydrate acts as a selective long-acting beta2-adrenergic agonist (LABA). By stimulating beta2-receptors in bronchial smooth muscle, formoterol activates intracellular adenylate cyclase, leading to muscle relaxation and bronchodilation. Compared to short-acting agents, formoterol provides prolonged relaxation of the airway smooth muscle, helping to maintain patent airways across a 12-hour dosing window.

Dosing Schedule

Dosage requirements vary based on the specific condition being treated and the patient’s age. For asthma management in adults and adolescents, the standard dosage is two inhalations of either the 80/4.5 mcg or 160/4.5 mcg strength twice daily, administered approximately 12 hours apart. For pediatric patients aged 6 to 11 years, the recommended dose is typically two inhalations of the 80/4.5 mcg formulation twice daily. For COPD maintenance in adults, the approved dosage is two inhalations of the 160/4.5 mcg strength twice daily.

Administration requires prime preparation prior to initial use or if the device has not been used for more than 7 days. Patients should shake the inhaler well for 5 seconds before each spray. Following inhalation, rinsing the mouth thoroughly with water and spitting it out without swallowing is essential to minimize systemic absorption and local oral side effects.

What Happens in the Body

Following oral inhalation, formoterol exhibits a rapid onset of bronchodilation, typically taking effect within 1 to 3 minutes, with peak plasma concentrations achieved approximately 6 minutes after administration. Budesonide demonstrates peak plasma concentrations within 20 minutes post-inhalation. The systemic bioavailability of inhaled budesonide is roughly 39% of the nominal dose, originating partly from pulmonary absorption and partly from swallowed drug passing through the gastrointestinal tract.

Both components undergo extensive hepatic metabolism. Budesonide is biotransformed primarily by the CYP3A4 enzyme into metabolites with low glucocorticoid activity. Formoterol is metabolized mainly by glucuronidation and O-demethylation. The plasma elimination half-life is approximately 4.7 hours for budesonide and roughly 10 hours for formoterol. Excretion occurs via both urinary and fecal pathways.

What You May Notice Early On

When starting treatment with Symbicort, patients often notice improved ease of breathing relatively quickly because formoterol initiates smooth muscle relaxation within minutes. However, evaluating the full therapeutic benefit of the anti-inflammatory component (budesonide) requires patience. While bronchodilation is immediate, maximum reduction in airway inflammation and optimal asthma control may take 1 to 2 weeks or longer of consistent, daily use.

During the first few days, minor transient sensations such as mild throat irritation or a slight tremor in the hands may occur. It is vital not to increase doses or stop treatment prematurely if symptom improvement is not immediate, as regular adherence is necessary to establish continuous anti-inflammatory protection.

Adverse Reactions

Like all prescription medications, Symbicort carries a potential for adverse effects. On one hand, many patients tolerate the inhaler well when used as directed; on the other hand, localized and systemic steroid exposure can trigger adverse reactions. The most frequently observed side effects include nasopharyngitis, headache, upper respiratory tract infections, pharyngolaryngeal pain, and sinusitis.

Localized fungal infections of the mouth and pharynx, specifically oral candidiasis (thrush), represent a known adverse outcome of inhaled corticosteroid use. Symptoms include white patches in the mouth and sore throat. Additional reported reactions include tremor, palpitations, muscle cramps, dysphonia (hoarseness), and cough. Less common but serious side effects include systemic corticosteroid effects such as hypercorticism, adrenal suppression, decreased bone mineral density, lower growth velocity in pediatric patients, glaucoma, and cataracts.

Compatibility With Other Medicines

Co-administration of Symbicort with strong cytochrome P450 3A4 (CYP3A4) inhibitors requires caution. Compounds such as ketoconazole, itraconazole, clarithromycin, and ritonavir can inhibit the metabolic clearance of budesonide, leading to increased systemic corticosteroid exposure and elevated risk of side effects. Concurrent use of non-potassium-sparing diuretics with beta2-agonists like formoterol may exacerbate electrocardiographic changes or hypokalemia.

Beta-adrenergic receptor blockers (beta-blockers), including those found in eye drops for glaucoma, may diminish or antagonize the therapeutic bronchodilating effect of formoterol and can precipitate severe bronchospasm in susceptible patients. Additionally, caution is advised when combining formoterol with other sympathomimetic agents, monoamine oxidase inhibitors (MAOIs), or tricyclic antidepressants due to potential additive cardiovascular effects.

Important Precautions

Symbicort should be prescribed with caution in patients with underlying cardiovascular conditions, including coronary insufficiency, cardiac arrhythmias, hypertension, and hypertrophic subaortic stenosis, as formoterol can produce beta-adrenergic stimulation affecting heart rate and blood pressure. Patients with pre-existing convulsive disorders, thyrotoxicosis, or unusual responsiveness to sympathomimetic amines also require close monitoring.

Long-term administration of inhaled corticosteroids necessitates monitoring for decreased bone density, particularly in patients with risk factors for osteoporosis. Pediatric growth should be tracked regularly. In pregnant patients, treatment decision-making balances potential risks against the established risks of uncontrolled asthma to the mother and fetus; clinical judgment by a prescribing physician is required.

If You Skip a Dose

If a scheduled dose of Symbicort is missed, the patient should skip that dose and take the next dose at the regularly scheduled time. Taking extra inhalations to make up for a missed dose is not recommended, as doubling doses increases the risk of beta-agonist and corticosteroid adverse effects, such as tachycardia and tremor.

What to Avoid While Taking It

Patients using Symbicort should avoid consuming large quantities of grapefruit or grapefruit juice, as grapefruit inhibits the hepatic enzyme CYP3A4 responsible for breaking down budesonide, potentially elevating systemic steroid levels. While alcohol does not directly interact with the chemical active ingredients in the inhaler, excessive alcohol intake can complicate underlying cardiovascular health and interfere with regular treatment routines.

Storage and Expiration

Symbicort should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). Store the canister with the mouthpiece pointing down. The canister should be kept away from extreme heat, direct sunlight, and freezing conditions. Do not puncture or incinerate the pressurized canister.

The inhaler includes a built-in counter that tracks remaining actuations. Discard the inhaler when the counter reads “0” or 3 months after removing the canister from its protective foil pouch, whichever comes first.

When to Seek Help Immediately

Red Flag Symptom Action Required
Sudden, severe tightness in the chest or worsening shortness of breath immediately after inhalation (paradoxical bronchospasm) Use a fast-acting rescue inhaler right away and seek emergency medical care immediately.
Signs of a severe allergic reaction (swelling of face, lips, tongue, throat; severe skin rash or hives) Discontinue use and get immediate emergency medical attention.
Chest pain, rapid or irregular heartbeat, severe dizziness Contact emergency medical services or go to an emergency room.
Signs of serious infection (high fever, persistent chills, worsening purulent cough) Contact your healthcare provider promptly for clinical evaluation.

Common Questions

Can Symbicort be used as a rescue inhaler during a sudden asthma attack?

No, Symbicort is formulated as a daily maintenance controller medication and should not be used as a primary rescue treatment for acute, sudden bronchospasm in the United States standard care setting. Patients must always carry a separate, fast-acting rescue inhaler (such as albuterol) to manage sudden attacks. If acute symptoms occur, rely on the rescue inhaler as instructed by your prescribing physician.

Why is rinsing the mouth recommended after each dose of Symbicort?

Rinsing the mouth with water and spitting it out without swallowing helps remove residual corticosteroid particles deposited on the oral mucosa during inhalation. This practical step significantly reduces the likelihood of developing local fungal infections, such as oral thrush (candidiasis), as well as throat irritation and hoarseness.

Does Symbicort cause systemic steroid side effects like oral prednisone?

Because Symbicort delivers budesonide directly to the lungs, systemic absorption is substantially lower compared to oral corticosteroid pills like prednisone. While high doses over prolonged periods can still potentially lead to systemic effects–such as decreased bone density or adrenal suppression–the risk is markedly reduced compared to systemic steroid therapy.

What should I do if my breathing worsens right after using the inhaler?

In rare cases, inhaled medications can cause an immediate increase in wheezing and respiratory distress, a condition known as paradoxical bronchospasm. If this occurs, stop using Symbicort immediately, use your short-acting rescue inhaler to relieve symptoms, and seek immediate emergency medical care.

Is it safe to stop taking Symbicort once my asthma symptoms improve?

You should not stop using Symbicort or change your dosing schedule without consulting your physician. Asthma and COPD are chronic conditions, and symptoms often decrease specifically because the daily anti-inflammatory medication is working. Abruptly stopping treatment can allow airway inflammation to return, increasing the risk of severe exacerbations.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

100 mcg + 6 mcg

,

200 mcg + 6 mcg

,

400 mcg + 6 mcg

Package

1 inhaler

,

2 inhaler

,

3 inhaler

Ενεργός Ουσία

,